Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
Sjogren disease has been a no-specific-systemic-therapy category for decades, managed with symptom relief and off-label immunosuppression. Recent pivotal readouts (BAFF-targeted ianalumab, CD40L-targeted dazodalibep, and other mechanism classes) are now establishing the first specific systemic therapy. The diagnostic-pathway question is significant; Sjogren disease is often diagnosed late, and rheumatology referral patterns shape the addressable population.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.